Krueger Sharon K, Siddens Lisbeth K, Henderson Marilyn C, Andreasen Eric A, Tanguay Robert L, Pereira Clifford B, Cabacungan Erwin T, Hines Ronald N, Ardlie Kristin G, Williams David E
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
Pharmacogenet Genomics. 2005 Apr;15(4):245-56. doi: 10.1097/01213011-200504000-00008.
Previous work defined two flavin-containing monooxygenase 2 (FMO2) alleles. The major allele, FMO22 (g.23,238C>T), encodes truncated inactive protein (p.X472) whereas the minor allele, FMO21, present in African- and Hispanic-American populations, encodes active protein (p.Q472). Recently, four common (27 to 51% incidence) FMO2 single nucleotide polymorphisms (SNPs) were detected in African-Americans (N=50); they encode the following protein variants: p.71Ddup, p.V113fs, p.S195L and p.N413 K. Our objectives were to: (1) determine the incidence of these SNPs in 29 Hispanic individuals previously genotyped as g.23,238C (p.Q472) and 124 previously genotyped as homozygous g.23,238 T (p.X472); (2) determine FMO2 haplotypes in this population; and (3) assess the functional impact of SNPs in expressed proteins.
SNPs were detected via allele-specific oligonucleotide amplification coupled with real-time or electrophoretic product detection, or single strand conformation polymorphism.
The g.7,700_7,702dupGAC SNP (p.71Ddup) was absent. The remaining SNPs were present but, except for g.13,732C>T (p.S195L), were less common in the current Hispanic study population versus the previously described African-Americans. Only expressed p.N413 K was as active as p.Q472, as determined by methimazole- and ethylenethiourea-dependent oxidation. Haplotype determination demonstrated that the g.10,951delG (p.V113fs), g.13,732C>T (p.S195L) and g.22,060T>G (p.N413 K) variants segregated with g.23,238C>T (p.X472).
SNPs would not alter FMO2 activity in individuals possessing at least one FMO21 allele. It is likely that these SNPs will segregate similarly in African-American populations. Therefore, estimates that 26% of African-Americans and 2-7% of Hispanic-Americans have at least one FMO21 allele should closely reflect the percentages producing active FMO2 protein.
先前的研究确定了两个含黄素单加氧酶2(FMO2)等位基因。主要等位基因FMO22(g.23,238C>T)编码截短的无活性蛋白(p.X472),而次要等位基因FMO21存在于非裔美国人和西班牙裔美国人中,编码活性蛋白(p.Q472)。最近,在非裔美国人(N = 50)中检测到四个常见的(发生率为27%至51%)FMO2单核苷酸多态性(SNP);它们编码以下蛋白质变体:p.71Ddup、p.V113fs、p.S195L和p.N413K。我们的目标是:(1)确定这些SNP在29名先前基因分型为g.23,238C(p.Q472)的西班牙裔个体和124名先前基因分型为纯合g.23,238T(p.X472)的个体中的发生率;(2)确定该人群中的FMO2单倍型;(3)评估SNP对表达蛋白功能的影响。
通过等位基因特异性寡核苷酸扩增结合实时或电泳产物检测或单链构象多态性检测SNP。
g.7,700_7,702dupGAC SNP(p.71Ddup)不存在。其余SNP存在,但除了g.13,732C>T(p.S195L)外,在当前西班牙裔研究人群中比先前描述的非裔美国人中更少见。通过甲巯咪唑和乙撑硫脲依赖性氧化测定,只有表达的p.N413K与p.Q472一样具有活性。单倍型测定表明,g.10,951delG(p.V113fs)、g.13,732C>T(p.S195L)和g.22,060T>G(p.N413K)变体与g.23,238C>T(p.X472)共分离。
SNP不会改变至少拥有一个FMO21等位基因个体的FMO2活性。这些SNP在非裔美国人中可能也会以类似方式共分离。因此,估计26%的非裔美国人和2 - 7%的西班牙裔美国人至少拥有一个FMO21等位基因,这应该能准确反映产生活性FMO2蛋白的百分比。